Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
Learn more about:
Related Clinical Trial
Co-administration Study of OCV, TCV and MR
TyVECO: Surveillance Protocol
Vellore Typhoid Vaccine Impact Trial
Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine ‘Typhocon’ in Bangladesh
Effectiveness of a Typhoid Conjugate Vaccine in DRC
Transcriptomic Responses for the Identification of Pathogens
Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana
Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants
Commercial Typhoid Tests Validation Trial
Commercial Typhoid Tests Validation
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)
Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers
Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants
Safety and Immunogenicity of Typhax, a Typhoid Vaccine
Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults
Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)
Investigating Enteric Fever – Salmonella Typhi and Paratyphi Challenge Study
Induction of Gut Permeability by an Oral Vaccine
Studies of Immune Responses to Orally Administered Vaccines in Developing Country
Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age
Typhoid Fever: Combined vs. Single Antibiotic Therapy
Vaccines Against Salmonella Typhi
Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine
Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
CVD 909 Vi Prime Boost Study
Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine
Global Genomic and Proteomic Profiling of African Children With Typhoid Fever
Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India
Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi
Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects
Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso
Understanding Typhoid Disease After Vaccination
Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China
Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam
Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children
Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine
Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood